Bad Ads, Badder FDA

By ACSH Staff — Jun 03, 2010
From the Manhattan Institute's Medical Progress Today "Second Opinion" section No one wants misleading pharmaceutical advertising, but the Food and Drug Administration's plan to deputize doctors to police drug companies is a misguided effort. Most physicians and health care workers simply don't have the hard data necessary to judge whether an ad overstates a drug's efficacy or plays down its risks. The hundreds of needless reports will distract the FDA from its core mission.

From the Manhattan Institute's Medical Progress Today "Second Opinion" section

No one wants misleading pharmaceutical advertising, but the Food and Drug Administration's plan to deputize doctors to police drug companies is a misguided effort.

Most physicians and health care workers simply don't have the hard data necessary to judge whether an ad overstates a drug's efficacy or plays down its risks. The hundreds of needless reports will distract the FDA from its core mission.

And the program isn't even limited to medical professionals; anyone will be allowed to file anonymous complaints. It's easy to imagine competitors or ideological activists trying to sabotage a new drug.

Ultimately, encouraging colleagues to report on colleagues is unprofessional and can only foster adversarial relationships between physicians and pharmaceutical companies.

Instead, why doesn't the FDA try training a small group of doctors and paying them a modest honorarium to monitor ads? This would give the agency a manageable amount of feedback, instead of the chaos of unlimited submissions.

ACSH relies on donors like you. If you enjoy our work, please contribute.

Make your tax-deductible gift today!

 

 

Popular articles